Q1 FY27 Results: Consolidated revenue up 28% YoY, PAT up 4.5%

Revenue Growth 20pctPat Growth 25pctRelated Party TransactionsResults View source PDF

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-3.4%1-day move

₹530.05

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-3.4-6.2-7.2-7.6-1.5—————

Up moveDown movePending

AI summary

Rossari Biotech reported Q1 FY27 consolidated revenue of Rs 697.2 crore, up 28% YoY from Rs 543.7 crore. Consolidated PAT rose to Rs 35.1 crore from Rs 33.6 crore. Standalone revenue grew 32% to Rs 482.3 crore, PAT up 31% at Rs 34.3 crore. Board granted 4000 ESOP options and approved transfer of Saudi arm RILC to Rossari Singapore for about Rs 24 crore as internal restructuring.

Likely market impact

Strong topline growth with moderate bottomline gain; ESOP grant and subsidiary transfer are routine corporate actions with no material impact.